Replies to post #5786 on Revance Therapeutics Inc (RVNC)

[alertmeipp]

Agree. Average revenue is forecasted to be around 620mm (range from 470 to 750mm)in 2026. Assume 75 percent margin and annual opex of 400mm, annual gross will be > 165mm

Refinancing won’t be a problem then.

Insider buy would help

15 percent short interest so lots of fuel when things recover

[DewDiligence]

...Foley will make a sizable ($500k+) open-market purchase after RVNC fully releases earnings.

That’s a reasonable inference from Foley’s having cancelled his 10b5-1 plan in Aug 2023 (#msg-173616050).

RVNC will report full 4Q23 results at the end of February, so the insider-trading blackout currently in effect should be over by early March.

[valiano]

No need to make it personal. I'm still long a partial and consider it a good reward to risk at this EV although near term upside is killed. I made the simple point that there's not much room for more slip ups. If they whiff the Therapeutics launch, there won't be material profits anytime soon. No profits -> questionable rollover.